Investor FAQs

On 22 September 2022, an Order was made by the Grand Court of the Cayman Islands (“Grand Court”) (the “Order”) appointing Margot MacInnis and John Royle of Grant Thornton Specialist Services (Cayman) Limited and Chow Tsz Nga Georgia of Grant Thornton Recovery & Reorganisation Limited as the Joint Provisional Liquidators of the Company (the “Joint Provisional Liquidators”). Upon the making of the Order, the powers of the directors of the Company are suspended. Blue Ocean Structure Investment Company Limited, a shareholder of the Company, filed a petition on August 22, 2022 in the Grand Court requesting the appointment.

Following the issuance of the Order, The New York Stock Exchange (the “NYSE”) halted trading in the Company's Ordinary Shares effective September 23, 2022.

Link to the Order made by the Grand Court of the Cayman Islands: https://www.sec.gov/Archives/edgar/data/1467808/000110465922102999/tm2226635d1_ex99-1.htm

What does Global Cord Blood Corporation do?

Our company provides umbilical cord blood storage services to enable parents to save the cord blood stem cells of their newborns to safeguard the lives and health of their children. We operate in China and the greater Asia Pacific region and were the first cord blood bank operator approved by the Ministry of Health of the People's Republic of China to engage in the cord blood banking business.

How many cord blood banking licenses does Global Cord Blood have access to in China?

We now have access to four cord blood banking licenses, which enable us to capitalize on the great market opportunities in the Beijing, Guangdong, Zhejiang and Shandong markets.

Where can I learn more about stem cell storage?

Please refer to the "Services" section of our website for detailed overview and services of cord blood banking services.

What is Global Cord Blood Corporation's ticker symbol and on what exchange does it trade?

We trade on the New York Stock Exchange under the ticker symbol, "CO."

Who is on Global Cord Blood Corporation's Board of Directors?

Pursuant to the Order of the Grand Court of the Cayman Islands (the “Order”), the powers of the existing Directors of Global Cord Blood Corporation (“GCBC”) are suspended.

The Joint Provisional Liquidators (“JPLs”) of GCBC have appointed corporate director entities controlled by the JPLs as directors to GCBC and its known subsidiaries.

Link to the Order made by the Grand Court of the Cayman Islands: https://www.sec.gov/Archives/edgar/data/1467808/000110465922102999/tm2226635d1_ex99-1.htm

How can I find information on Global Cord Blood Corporation's SEC filings?

Our filings with the SEC may be obtained by accessing the "Financial Information" link in the "Investor Relations" section on our website or by visiting www.sec.gov.

When does Global Cord Blood Corporation's fiscal year end?

Our fiscal year ends on March 31.

How can I contact management?

Please see the IR Contact page in the Investor Relations section of this website for details of how to direct investor enquiries.

Are there any material differences in Global Cord Blood Corporation's corporate governance practices from those of U.S. domestic companies under the NYSE listing standards?

We are incorporated under the laws of the Cayman Islands, our home country, with securities publicly traded in the United States on the NYSE. The NYSE Rules permit foreign private issuers to follow applicable home country corporate governance practices in lieu of the NYSE corporate governance standards, subject to certain exceptions. Foreign private issuers electing to follow home country corporate governance rules are required to disclose the principal differences in their corporate governance practices from those required under the NYSE Rules. Except as set forth in the "Corporate Governance - Highlights" in the "Investor Relations" section in our website, there are no material differences in the Company's corporate governance practices from those of U.S. domestic companies under the listing standards of the NYSE.